Rothschild Investment LLC Has $961,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Rothschild Investment LLC lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,981 shares of the medical research company’s stock after buying an additional 263 shares during the quarter. Rothschild Investment LLC’s holdings in Edwards Lifesciences were worth $961,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences in the 4th quarter worth about $30,000. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the third quarter worth approximately $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $32,000. Avior Wealth Management LLC boosted its stake in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the period. Finally, Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $46,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other news, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,489 shares of company stock worth $2,002,829. Corporate insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of several analyst reports. Evercore ISI dropped their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Piper Sandler boosted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Finally, Truist Financial reissued a “hold” rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Price Performance

Shares of EW opened at $72.72 on Tuesday. The business has a 50-day moving average of $72.83 and a 200-day moving average of $70.13. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a market capitalization of $42.89 billion, a price-to-earnings ratio of 10.43, a price-to-earnings-growth ratio of 4.82 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.